Chih-Yi Hsu, Hsiang-Ling Ho, Shih-Chieh Lin, Ming-Hsiung Chen, Sanford P-C Hsu, Yu-Shu Yen, Wan-Yuo Guo, Donald Ming-Tak Ho
The O-methylguanine-DNA-methyltranferase (MGMT) status is a powerful predictor of response to temozolomide for newly diagnosed glioblastoma (GBM) patients, and it is commonly assessed by immunohistochemistry (IHC), methylation-specific polymerase chain reaction (MSP), quantitative real-time MSP (qMSP), and/or pyrosequencing (PSQ). This study was to compare their predictive power of prognosis in 121 newly diagnosed GBM patients using multivariate Cox regression with bootstrapping. MGMT status tested by IHC, MSP, qMSP, or PSQ all showed significant correlation with the progression-free survival and overall survival of GBM patients...
August 2017: Applied Immunohistochemistry & Molecular Morphology: AIMM